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Communiqué
Heart failure (HF) is a common and highly morbid disorder. An estimated 5 million people in the United States have HF, and it is diagnosed in 500,000 new patients each year. For individuals older than 40 years, the lifetime risk of developing HF has been estimated at 20% for both men and women. The incidence of HF is highest in people older than 65 years, a rapidly growing segment of our population, ensuring an epidemic of HF that will continue to grow as the population ages.
Heart failure is a syndrome associated with perturbations in cardiac structure and function that result from various cardiovascular diseases. The diagnosis of HF is a clinical one based on symptoms, signs, chest radiographs, and response to therapy. Echocardiography is used to characterize the specific structural and functional abnormalities associated with the syndrome but does not determine the diagnosis of HF.
Diagnosing HF often can be extremely difficult, and both underdiagnosis and overdiagnosis are common. This is true especially in the elderly population, obese individuals, patients who are deconditioned, and those with an underlying lung disease. Symptoms and signs may be difficult to evaluate in patients who are in acute respiratory distress, when rapid diagnosis and therapy are needed. Many physicians attempt to confirm their suspicion of HF by obtaining an echocardiogram to detect the presence of systolic dysfunction. However, studies have shown repeatedly that 50% of patients presenting with well-established clinical HF have normal systolic function (diastolic HF [DHF] ). Furthermore, 50% of patients with systolic dysfunction have no symptoms of HF (asymptomatic ventricular dysfunction). Thus, a low ejection fraction (EF) is not synonymous with the diagnosis of HF. Finally, access to echocardiography is limited in urgent care settings. For these reasons, there has been intense interest in an inexpensive, widely available, easily interpreted diagnostic aid that reflects the physiology common to patients with systolic HF and DHF.
Physiology of BNP
The natriuretic peptide family includes BNP, atrial natriuretic peptide (ANP), and C-type natriuretic peptide. Both BNP and ANP are of myocardial cell origin, whereas C-type natriuretic peptide is of endothelial cell origin. These hormones are important for volume homeostasis and for regulation of blood pressure. The physiological actions of the natriuretic peptide system include arterial and venous dilatation, natriuresis, and suppression of the renin-angiotensin-aldosterone system and the sympathetic nervous system. These peptides also may exert autocrine-paracrine effects, acting on the heart to inhibit fibrosis and hypertrophy and enhance diastolic function. Pressure and volume overload of the cardiac chambers stimulate enhanced production and release of natriuretic peptides. Thus, these peptides reflect the common denominator present in patients with systolic or diastolic dysfunction, volume overload, and HF, regardless of the underlying cardiovascular disease.
Other forms of natriuretic peptides, such as proBNP and N-terminal proBNP, are being evaluated currently. Although a discussion of these other peptides is beyond the scope of this article, it is notable that these new assays will soon be available to aid in the diagnosis of HF. More recently, a study performed in a Veterans Administration hospital included 250 relatively young (mean age of 64 years) male patients who presented to the ED with dyspnea. Routine clinical parameters, echocardiograms, chest radiographs, and other clinical data were collected. This study revealed that the BNP level was elevated markedly in those deemed to have HF compared with those believed to have a pulmonary etiology for the dyspnea. A receiver operating characteristics (ROC) analysis showed that the area under the ROC curve for BNP for the diagnosis of HF was exceptionally high at 0.97, indicating near-perfect sensitivity and specificity.
The Breathing Not Properly Multinational Study was a prospective multicenter study of 1586 patients presenting to the ED with the chief complaint of dyspnea. The Triage BNP Test was used to measure plasma levels of BNP. The diagnosis of HF was established by an independent panel of cardiologists who had access to all clinical data obtained in the ED evaluation and in the subsequent hospital course. In this study, the ED physicians were required to designate a diagnosis of either HF or noncardiac dyspnea. The physicians were also required to provide an estimate of their confidence in the diagnosis of HF. If they were at least 80% confident in the diagnosis of HF, the ED diagnosis was considered HF. This study then compared the clinical diagnosis of HF and its accuracy to that obtained by plasma BNP concentrations. As in the single-center study, plasma BNP levels were elevated in patients with HF ( Figure 1 ). Patients who had known systolic dysfunction but were believed to have a different etiology of their acute dyspnea had BNP levels that were intermediate, between those with HF and those with noncardiac dyspnea. Although the accuracy of the clinical diagnoses and BNP diagnoses was similar, the clinical test was more sensitive but less specific than clinical judgment (Table 1) . A plasma BNP value of 100 pg/mL was deemed the best cutoff value in this study. Use of higher concentrations yielded better specificity but less sensitivity. A Bayesian-type analysis suggested that BNP was most helpful when the diagnosis of HF was intermediate. This concept is common to all diagnostic tests, particularly to the use of exercise testing in the diagnosis of coronary artery disease. Therefore, the investigators suggested that BNP is best used when the physician suspects HF but is unsure of the diagnosis. 
Confounding Variables
Detection of Mild HF BNP levels increase in relation to the severity of CHF. Thus, BNP levels are highest in patients with the most severe HF. However, data in outpatients indicate that use of BNP tests enhances the diagnosis of HF, even in patients with milder HF being seen as outpatients.
Diagnosis of Diastolic Heart Failure
An important issue is whether BNP levels can be used for accurate diagnoses of diastolic heart failure (DHF). Recent studies suggest the BNP test is an excellent diagnostic tool because BNP levels are elevated in patients presenting with DHF. 
Lung Disease with Cor Pulmonale

Flash Pulmonary Edema
Of note, some patients with extremely rapid onset of pulmonary edema seen within the first hours of onset of symptoms may have a normal or low BNP level because it takes time for the production and release of BNP to be augmented in response to an acute increase in filling pressures.
Renal Insufficiency and Renal Failure
There has been some speculation that BNP levels are falsely elevated in patients with underlying renal impairment; however, this does not seem to be the case. Cataliotti et al showed that among patients with endstage renal disease, the BNP level is elevated only in those with concurrent left ventricular hypertrophy. In the absence of left ventricular hypertrophy, the BNP level was not elevated. These data are consistent with the fact that BNP is not cleared primarily by the kidney but is degraded by endopeptidases and clearance receptors throughout the body. (Figure 2 ). Indeed, in women older than 65 years, the 95th percentile value for BNP is well over 100 pg/mL and can be as high as 155 pg/mL. Furthermore, the BNP level increases with severity of symptoms, suggesting that the test should be interpreted in relation to severity of symptoms and BNP level.
Although each institution may develop specific guidelines for interpretation of the BNP test, our institution reports the BNP level in reference to agespecific and sex-specific 95th percentile reference values established in a large population of normal subjects from the community (Figure 2 ). The Figure 2 legend includes results of a BNP assay that relate the severity of symptoms to the expected BNP level, with he following interpretation guide: BNP level higher than normal but less than 200 pg/mL = likely compensated congestive heart failure (CHF); BNP level of 200 to 400 pg/mL = likely moderate CHF; BNP level higher than 400 pg/mL = likely moderate to severe CHF.
Standard Care
Approved to aid in the diagnosis of HF, the BNP assay does not replace, but rather augments, clinical evaluation. Heart failure must be clinically diagnosed by using data obtained from the patient's history, physical examination, and chest radiographs. However, the BNP test may lead to more efficient and accurate diagnoses of this syndrome and prove helpful to the physician. Of note, the strongest evidence so far for use of BNP pertains to its use in the diagnosis of HF. Therefore, it should be ordered when there is uncertainty about the proper diagnosis. For example, use of BNP testing in a patient with a known EF of 20% and a history, physical examination, and chest radiograph clearly indicative of HF adds nothing with respect to diagnosis. Conversely, a BNP test would be extremely helpful in a patient whose history, physical examination, and chest radiograph are suggestive of, but not clearly indicative of, HF. In this case, the "pretest" probability of HF is intermediate; therefore, the BNP test may help the physician make the correct diagnosis more rapidly. In this patient, if the BNP level is above normal, suspicion rises greatly with respect to the diagnosis of HF. However, if the BNP level is normal, this suggests the patient has noncardiac dyspnea.
The severity of symptoms also may influence the interpretation of the test. The more severe the symptoms, the higher the BNP level should be if the symptoms are due to HF. Thus, a minimally elevated BNP level in a patient with gradual onset of severe dyspnea at rest and an intermediate probability of HF is not as useful.
In conclusion, as with all diagnostic tests, BNP tests can be helpful for diagnosing HF in patients in whom the diagnosis is not obvious and the pretest probability is intermediate. As always, the physician must remember that the diagnosis of HF is not made solely on the basis of a laboratory test or an echocardiogram, but rather on clinical grounds; these tests are used to augment clinical judgment. Recognizing the wide variety of potential specimen sources, there are no reference values for this test and each specimen must be evaluated on an individual basis. For this reason, whenever possible a serum specimen should be submitted along with the body fluid specimen. Both the serum and the body fluid samples will be tested, providing a better framework for interpretation of the individual patient's results. The serum test is performed free of charge as part of the body fluid test. Please be sure to label each specimen appropriately as either "serum" or "body fluid." Specific information on the source/location of the body fluid also should be included with the specimen.
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